Anti-Inflammation Compounds

A method for treating an inflammatory disease, comprising the application or administration, to a patient in need of such treatment, of an effective amount of a compound having the general formula I:

• wherein
• n is 0, 1, 2, or 3;
• m is 0, 1, 2, or 3;
• o is 0, 1, 2, or 3;
• W, X, Y and Z are independently selected from CH, N or N-oxide;
• A is NR4, C═O, C═S, OP(O), P═O, CH2, or a heteroaryl selected from the group consisting of
• V is C═O, O, S, CH2 or NR5;
• R1 is a moiety selected from the group consisting of
• m and n being, independently at each occurrence, selected from 0, 1, 2 or 3;
• R2 is, at each occurrence, independently, selected from the group consisting of hydrogen, halogen, C1-C10 alkyl, C3-C10cycloalkyl, C2-C10 alkenyl, C3-C10 cycloalkenyl, C2-C10alkynyl, C1-C10haloalkyl, —OH, —OR5, C1-C10 alkoxy, C3-C10cycloalkoxy, C3-C15cycloalkylalkoxy, C3-C15cycloalkylalkyl, —CN, —NO2, —NH2, —N(R5)2, —C(O)R5, —C(O)OR5, —C(O)N(R5)2, —P(O)OR5, —P(O)OR5N(R5)2, —SR5, —S(O)R5, —S(O)2R5, —S(O)2N(R5)2, aryl, and heterocyclyl, any of which is optionally substituted;
• R3 is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C10 alkyl, C3-C10cycloalkyl, C1-C3 haloalkyl, hydroxyl, —OR6, —CN, —NO2, —NH2, —N(R6)C(O)R6, —C(O)R6, —C(O)OR6, —C(O)N(R6)2, —S(O)R6, —S(O)2R6, —S(O)2N(R6)2, aryl, and heterocyclyl, any of which is optionally substituted, or two groups of R3 are connected to each other to make a five or six membered cyclic or heterocyclic ring, any of which is optionally substituted;
• R4 and R5 are, at each occurrence, independently selected from the group consisting of hydrogen, C1-C10 alkyl, C3-C10cycloalkyl, C2-C10 alkenyl, C3-C10 cycloalkenyl, C2-C10alkynyl, C1-C10haloalkyl, —OH, —OR7, C1-C10 alkoxy, C3-C10cycloalkoxy, C3-C15cycloalkylalkoxy, C3-C15cycloalkylalkyl, —NH2, —N(R7)2, —C(O)R7, —C(O)OR7, —C(O)N(R7)2, —S(O)R7, —S(O)2R7, —S(O)2N(R7)2, aryl, and heterocyclyl, any of which is optionally substituted;
• R6 is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C10 alkyl, C3-C10cycloalkyl, C2-C10 alkenyl, C3-C10 cycloalkenyl, C2-C10alkynyl, C1-C10haloalkyl, hydroxyl, —OR8, —C(O)R8, —R(R8)C(O)R8, —C(O)OR8, —R8(R8)C(O)OR8, —CN, —NO2, —NH2, —N(R8)2, —C(O)N(R8)2, —R8(R8)C(O)N(R8)2, —S(O)R8, —S(O)2R8, —S(O)2N(R8)2, aryl, and heterocyclyl, any of which is optionally substituted;
• R7 is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C10 alkyl, C3-C10cycloalkyl, C2-C10 alkenyl, C3-C10 cycloalkenyl, C2-C10alkynyl, C1-C10haloalkyl, aryl, and heterocyclyl, any of which is optionally substituted;
• and
• R8 is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C8 alkyl optionally substituted with at least one hydroxyl or halogen;
• C3-C7cycloalkyl, C2-C10 alkenyl, C3-C10 cycloalkenyl, C2-C10alkynyl, C1-C10haloalkyl, aryl, and heterocyclyl, any of which is optionally substituted,
• or a pharmaceutically acceptable salt thereof.